NAT2
HGNC ↗4 article(s) in the watch · Pharmacogenomics
NAT2 determines acetylator status (slow/fast), modulating the metabolism of drugs such as isoniazid, sulfasalazine and some amines. Slow acetylators are more prone to certain adverse effects.
Drugs involved: isoniazid, hydralazine, sulfonamides
Recommendation: Emerging evidence
Curated publications
Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel
NAT2 acetylator status and drug response
Characterization of NAT2 Using Long-Read Sequencing: Allele, Diplotype, and Phenotype Call Accuracy Compared to Other Testing Strategies.
Acetylator status and NAT2 pharmacogenetic typing
Impact of NAT2 acetylation phenotype on toxicity in tuberculosis therapy: a systematic review and meta-analysis
Anti-tuberculosis drug-induced hepatotoxicity
Acetylation Variability in Elderly Tunisians: Implications for Isoniazid Dose Individualization.
Tuberculosis — NAT2 acetylation variability, isoniazid dose individualization in elderly patients
Frequently asked questions
Which drugs are affected by NAT2 in pharmacogenomics?+
isoniazid, hydralazine, sulfonamides — Emerging evidence
How many Geno'X publications cover the NAT2 gene?+
4 publication(s) on NAT2 have been selected, summarised and scored by Geno'X on a public grading grid (domains: Pharmacogenomics).
